Zacks Investment Research
15 Jul 2026, 13:51 UTC · 1h ago
Thermo Fisher Set to Report Q2 Earnings: What's in the Cards?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
15 Jul 2026, 13:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The Zacks Consensus Estimate for TMO's Q2 revenue is $11.68 billion, a projected 7.6% increase year-over-year. — Projected revenue growth indicates positive fundamental momentum and growth expectations for the company.
+0.30TMO's consensus EPS estimate for the quarter is $5.71, representing a 6.5% year-over-year increase. — Expected growth in profitability is a primary driver for stock price appreciation.
+0.30Thermo Fisher Scientific (TMO) is scheduled to release its second-quarter 2026 financial results on July 23. — Earnings dates create immediate volatility and focal points for traders regarding the specific stock.
+0.20Continue reading
6 related stories
Top 3 movers · tap to explore
Thermo Fisher has acquired Solventum’s Filtration and Separation business to enhance its Bioproduction offerings. — Strategic acquisitions expand capabilities and market share, though integration risks exist.
Which stocks this story touches
Positive projections for Q2 2026 results, consistent earnings beats, and strategic product launches and acquisitions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
